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Primary cardiac arrhythmias are often caused by defects, predominantly in the genes
responsible for generation of cardiac electrical potential, i.e., cardiac rhythm generation.
Due to the variability in underlying genetic defects, type, and location of the mutations and
putative modifiers, clinical phenotypes could be moderate to severe, even absent in many
individuals. Clinical presentation and severity could be quite variable, syncope, or sudden
cardiac death could also be the first and the only manifestation in a patient who had pre-
viously no symptoms at all. Despite usual familial occurrence of such cardiac arrhythmias,
disease causal genetic defects could also be de novo in significant number of patients.
Long QT syndrome (LQTS) is the most eloquently investigated primary cardiac rhythm
disorder. A genetic defect can be identified in ∼70% of definitive LQTS patients, followed
by Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Brugada syndrome
(BrS), where a genetic defect is found in <40% cases. In addition to these widely investi-
gated hereditary arrhythmia syndromes, there remain many other relatively less common
arrhythmia syndromes, where researchers also have unraveled the genetic etiology, e.g.,
short QT syndrome (SQTS), sick sinus syndrome (SSS), cardiac conduction defect (CCD),
idiopathic ventricular fibrillation (IVF), early repolarization syndrome (ERS). There exist also
various other ill-defined primary cardiac rhythm disorders with strong genetic and familial
predisposition. In the present review we will focus on the genetic basis of LQTS and its
clinical management. We will also discuss the presently available genetic insight in this
context from Saudi Arabia.
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INTRODUCTION
Familial or hereditary cardiac arrhythmias comprise significant
percentages of arrhythmias and also causal to sudden cardiac
death (SCD) (1, 2). During the last two decades, scientists and
clinicians have provided enormous effort to unravel the intri-
cate and complex mechanisms of congenital familial arrhythmias
(1–8). To understand the mechanism of arrhythmogenesis, we
need to know the basics of cardiac cellular structure and their
electrophysiological properties. Cardiac myocytes are the major
functioning cells in the heart and they are extensively coupled so
that impulses propagate rapidly and uniformly. Cardiomyocytes
are separated from each other by a specialized boundary called
the intercalated disk; gap junction proteins, cardiac desmosomes,
and ion channels are located in the intercalated disk (9). Gap
junctions consist of tightly packed connexins which permit inter-
cellular exchange of small molecules and also permit to flow the
excitatory currents from one cell to its neighboring cell. Desmo-
somes along with the adherens junctions are responsible for the
mechanical attachments of individual cardiomyocytes. All these
components in the intercalated disks are sequentially segregated
and each component exerts its unique function; disruption of the
one component affects the function of other components, which
predisposes the heart to develop arrhythmias (9–11). Cardiac ion
channels are pore-forming protein complexes that provide voltage
gated and intricately coordinated inward and outward movement
of ionic currents across the cell membranes, essential for cardiac
rhythm generation and propagation. Long QT syndrome (LQTS),
short QT syndrome (SQTS), sick sinus syndrome (SSS), cardiac
conduction defect (CCD), BrS, catecholaminergic polymorphic
ventricular tachycardia (CPVT), early repolarization syndrome
(ERS), and familial Atrial Fibrillation (AF) are the presently known
cardiac channelopathies, which could occur due to a single or mul-
tiple defect in the genes linked to cardiac rhythm generation and
propagation.
In this review, we will describe exclusively on LQTS linked
arrhythmias, its pathophysiology and presently available clinical
management. We have pioneered in elucidating genetic pathology
in familial cardiac arrhythmias in Saudi Arabia (1, 12–14), we are
still conducting cardiogenetic investigations in Saudi Arabia, at the
end of this review, we will discuss the presently available knowledge
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about the genetic and clinical findings obtained from several Saudi
Arabian families with history of syncope and SCD. We will also add
the recently published data on LQTS from a team at King Faisal
Specialist Hospital and Research Centre, Riyadh (15).
LONG QT SYNDROME
Congenital LQTS is an inherited disorder defined by prolongation
of the QT interval on electrocardiogram (ECG). Patients with all
forms of LQTS are predisposed to the ventricular tachyarrhythmia,
torsades de pointes (TdP) leading to recurrent syncope, or SCD.
In many instances, syncope or sudden death could be the first and
the only manifestation. LQTS affects an estimated 1 in 2,000 peo-
ple worldwide (16). The hallmark of the LQTS is prolongation
of the QT interval on ECG (corrected for heart rate, i.e., QTc).
Normal values of QTc are 440 ms in males and 450 ms in females.
In children, age and gender dependent values are relevant. Recent
consensus recommendation for LQTS diagnosis are the following
(17, 18):
1. LQTS is diagnosed:
a. In the presence of an LQTS risk score≥3.5 in the absence of
a secondary cause for QT prolongation and/or
b. In the presence of an unequivocally pathogenic mutation in
one of the LQTS genes or
c. In the presence of a QT interval corrected for heart rate
using Bazett’s formula (QTc) ≥500 ms in repeated 12-lead
electrocardiogram and in the absence of a secondary cause
for QT prolongation.
2. LQTS can be diagnosed in the presence of a QTc between 480
and 499 ms in repeated 12-lead ECGs in a patient with unex-
plained syncope in the absence of a secondary cause for QT
prolongation and in the absence of a pathogenic mutation.
Patients with QTc duration ≥500 ms had a significantly higher
cumulative probability of experiencing their first syncope as com-
pared to patients with QTc duration<500 ms from birth through
age 20 years (19). But, patients who have experienced 2, 3, and 4
syncope episodes, the risk of a subsequent syncope episode was
virtually identical between patients who had narrow or prolonged
QTc duration (19). The molecular basis of LQTS is heterogeneous
and to date, mutations in 13 different genes have been described
causal to LQTS (1–8, 19, 20). A genetic defect is usually found
in 70% of the LQTS patients in one of these 13 genes (1–8, 19,
20). Among the presently known 13 different types of LQTS, the
most common are LQTS1, LQTS2, and LQTS3, due to defects in
cardiac ion channel genes, KCNQ1, KCNH2, and SCN5A, respec-
tively. Ninety percent of all the LQTS causal mutations are found
in these three genes (1–8, 19, 20). Mutations in the remaining 10
genes are rare and comprise only∼10% of all the presently known
LQTS mutations.
Long QT syndrome is usually an autosomal dominant disease,
but, occasionally, multiple mutations in a single gene or in differ-
ent genes could be found in 5–10% of the patients with LQTS (21,
22). Patients with multiple mutations could exhibit a longer QTc
compared with those with a single mutation and such patients are
also at ∼3.5-fold increased risk for life-threatening cardiac events
(21, 22)
LQTS1
Mutations in the KCNQ1 gene are the commonest form of all
LQTS and referred as LQTS type 1 (LQTS1). Fifty percent of all
the LQTS causal mutations are found in the KCNQ1 gene (20).
KvLQT1 (also called Kv7.1) is a protein made by the KCNQ1 gene
and the protein forms tetramers in the endoplasmic reticulum
inside the cells, which putatively co-assembles with the protein
minK (encoded byKCNE1) and are then transported to the plasma
membrane of the cardiac myocytes, where they mediate a slowly
activating current which accelerates the repolarization of action
potential in cardiac tissues, this current is known as IKs (Figure 1).
LQTS1 causal KCNQ1 mutations are mostly missense mutations
and in rare instances they could be frameshift mutations in the
C-terminal region (23). Cardiac arrhythmia in KCNQ1 mutation
carriers are triggered by adrenergic drives, e.g., emotional stress,
physical exertion, diving, swimming (24–26). Patients with muta-
tions at the transmembrane domains of KvLQT1 are at higher risk
of LQTS-related cardiac events and have greater sensitivity to sym-
pathetic stimulation (26, 27). Patients with missense mutations are
at increased risk compared to patients with non-sense or truncat-
ing mutations (27, 28). Variation in the 3′-UTR in the KCNQ1
gene also affects the arrhythmia susceptibility significantly, pre-
sumably by impacting on the expression of the gene (29). Patients
with arrhythmias due to KCNQ1 mutations respond quite well to
β-blockers, but, some patients could still be less responsive or even
resistant to this medication. In a recent article, Barsheshet et al.
(30) claimed that the patients with mutations outside the cyto-
plasmic loop (c-loop) region in the KvLQT1 are less responsive to
β-blockers.
Homozygous or compound heterozygous mutations in the
KCNQ1 gene, which could cause the recessive form of the disease,
Jervell and Lange-Nielsen syndrome (JLNS), type 1 (31), are quite
rare. JLNS patients suffer from severe cardiac arrhythmias and
deafness as well (31, 32). Patients with KCNQ1 mutations causal
to JLNS usually do not have any functional IKs (28, 31–33). It is
possible that some patients could have no deafness despite having
homozygous or compound heterozygous mutations in KCNQ1,
such cases are referred as autosomal recessive LQTS1 (13, 32). In
these patients, small amount of functional IKs current (<10% of
total IKs) could still be present, which maintains the hearing func-
tion, but, their cardiac rhythm defects are equally severe like in
JLNS patients (13, 32).
LQTS2
This type of LQTS is equally prevalent as LQTS1, accounting for
35–40% of LQTS patients with a detectable mutation (1, 20, 24,
25). KCNH2 encodes for the HERG protein (Kv11.1), which is the
α-subunit of the rapidly activating delayed rectifier K+ current
(IKr). Pathogenic mutations in this gene that reduces the Kv11.1
channel function prolongs duration of the QT interval (Figure 1),
and are causal to LQTS2. Twenty-nine percent of the syncopal
attacks in LQTS2 occur during rest/sleep and only 13% of the
syncopal attacks were reported to occur during exercise (25, 34).
Sudden startling noises, e.g., alarm clock rings, doorbells, tele-
phone rings, typically trigger syncopal attacks in these patients
(24, 34). Patients with mutations in the pore-forming region of
the Kv11.1 (encoded by KCNH2 gene) are susceptible to high risk
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FIGURE 1 | Ionic currents contributing to the ventricular action potential
(A) and schematic representation of a cardiomyocyte displaying (only)
those proteins involved in the pathogenesis of inherited arrhythmia
syndromes (B). In (A), the action potential is aligned with its approximate
time of action during the ECG. In (B), ankyrin-B, an adapter protein involved in
the long QT syndrome type 4, is not depicted.
for arrhythmia-related cardiac events compared with patients with
non-pore region mutations (35). In neonates, 2:1 Atrioventricu-
lar (AV) block is preferentially associated with KCNH2 mutations
(36). Complete AV block complicated by LQTS were also found in
17% of adult patients with a mutation in the KCNH2 gene (37).
Homozygous mutations in KCNH2 are rare and when present,
patients suffer from a severe form of LQTS, with 2:1 AV block and
severe ventricular arrhythmias, during intrauterine stages as well
as after birth (11, 38–40). In addition to the numerous mutations
described in LQTS2 pathology, common polymorphic variants
in the KCNH2 gene could also modulate the disease severity. An
intriguing example is K897T polymorphism (SNP) in KCNH2,
which is present in 33% of the general population (41). K897T was
reported to exacerbate the pathogenicity of the KCNH2 mutations
(42, 43).
LQTS3
Nav1.5 is the pore-forming α-subunit of the voltage-dependent
cardiac Na+ channel, it is an integral membrane protein encoded
by the SCN5A gene and is involved in the initiation and conduction
of cardiac action potentials. Cardiac Na+ channels are composed
of a pore-forming α-subunit (encoded by SCN5A) and one or
more auxiliary β-subunits.
LQTS3 is caused by gain of function mutations that disrupt
fast inactivation of the α-subunit (Figure 1) and a mutation in the
SCN5A gene have been described in <10% of all LQTS patients
with a mutation (1, 20, 24). LQTS3 patients experience the major-
ity (39%) of their cardiac events during sleep/rest (25), and about
∼13% of the events were reported to occur during exercise (25).
In several instances, a single SCN5A mutation was shown to exert
two or even three distinct phenotypes of arrhythmias in the same
family, e.g., LQTS, BrS, or CCD (44–47). Male patients with a
LQTS3 mutation could develop symptoms much earlier than the
female patients (48). Both heterozygous and homozygous SCN5A
mutations have been described in LQTS3 with functional 2:1 AV
block (49). We have recently found an Iranian family with the
1507_1509delQKP mutation in multiple family members, where
patients had combined LQTS and CCD (data not shown). This
mutation has been reported in patients from other countries as
well, which suggests that this is a recurrent and hot spot mutation
[(49, 50) and our unpublished data]. Mutations with such a loss-
and gain-of-function characteristics during different phases of the
action potential were also reported in 1493delK and 1795insD
mutations (44, 51).
Occasionally, an SNP could also exert pathogenic effect on its
carriers. S1103Y is a common variant in the SCN5A gene, present
in 13% of the African Americans (52). Carriers with this vari-
ant are at increased risk of arrhythmias and sudden infant death
syndrome (SIDS) (52).
LQTS4
LQTS4 represents the first non-channel form of LQTS. A muta-
tion in the ANK2, an adapter protein, leads to intracellular calcium
overload which contributes to the LQTS4 (53, 54). In addition to
QT prolongation, patients with this syndrome could have sinus
bradycardia, paroxysmal AF, and CPVT (54). Pathogenic effect of
the ANK2 mutations could be moderate to severe and the clinical
expressions depend on the severity of the mutation.
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LQTS5
Mutations in KCNE1 are associated with the LQTS5 (Figure 1)
(55, 56). Heterozygous KCNE1 mutations reduce IKs by exert-
ing a dominant negative effect on its accompanying normal allele,
and lead to delayed cardiac repolarization (Figure 1), responsible
for increased risk of arrhythmias (6). Patients with homozygous
KCNE1 mutations suffer from JLNS (type 2) (57, 58).
D85N is a polymorphism in the KCNE1 gene, present in 0.7–
1% of the general population (41). In a study by Nishio et al. (59),
D85N polymorphism was more frequently found in the LQTS
patients, making it a risk genotype in LQTS pathology (potentially
only in the Asian population). In Europe, D85N was reported in
5% of acquired LQTS (aLQTS) patients (in a cohort of 32 patients),
who had experienced TdP (60).
LQTS6
KCNE2 gene encodes for MinK-related peptide 1 (MiRP1), a puta-
tive β-subunit of the cardiac potassium channel IKr (Figure 1).
Mutations in KCNE2 gene could also lead to defects in the rapidly
activating component of the delayed rectifier potassium current
(IKr), pathologic basis of LQTS6 (61). Auditory/acoustic stimulus
like alarm clock noise, doorbell etc. could provoke syncopal attacks
in KCNE2 mutation carriers, similar to KCNH2 mutation (62).
LQTS7
This syndrome is also known as Andersen–Tawil syndrome (ATS).
ATS is a rare disorder, manifested by occasional syncope, and car-
diac arrest. ECG features include mild QT interval prolongation,
abnormal U waves, frequent ventricular ectopy, bidirectional ven-
tricular tachycardia (VT), and polymorphic VT. This syndrome
also exhibits extracardiac features, e.g., skeletal muscle periodic
paralysis and developmental problems, such as cleft palate, low set
ears, short stature, and developmental defects in the limbs (63).
Majority of clinically diagnosed ATS patients were reported to have
a mutation in KCNJ2 (63). KCNJ2 encodes a pore-forming sub-
unit of inwardly rectifying potassium channels (IK1) (Figure 1)
(64, 65).
LQTS8
Also known as Timothy syndrome (TS), patients show severe
QT prolongation on their ECGs, which is combined with syn-
dactyly, baldness at birth, and small teeth in 100% of cases and
less penetrant cardiac structural malformations, mental retarda-
tion, autism, and facial dysmorphic features (66). There are two
subtypes: TS1 (classical) and TS2 (rare form).
TS2 is cardiologically severer than TS1 (66, 67). TS2 patients
also lack syndactyly (67). Mutations in the α-1 subunit of the L-
type calcium current (ICa-L) encoding gene CACNA1C lead to
both forms of TS (LQTS8). There are alternatively spliced, mutu-
ally exclusive exon-8 in the CACNA1C gene, for clarity, they are
named as exon-8 and exon-8A. In heart and brain, where the
CACNA1C is predominantly expressed, exon-8 is found in∼80%
of the mRNA transcripts and exon-8A is present∼20% transcripts
(66). G406R mutation in exon-8A is causal to classic form of TS
(TS1) and G402S in exon-8 was reported in severer in TS2. A
new addition to this list is Ala1473Gly mutation, which has been
described in a TS infant with further expanded phenotype (68).
All mutations were either de novo or mosaic in the parent, and all
result gain of function of the ICa-L channel (66–69).
LQTS9 AND LQTS10
Mutations inCAV3 or SCN4B produce gain of function in late INa,
causing an LQTS3-like phenotype (70–74). They are known as
LQTS9 (associated with CAV3 mutation) and LQTS10 (associated
with SCN4B mutation).
Caveolae are nicely described by Engelman et al. (72) as “lit-
tle caves” in the plasma membrane. They are small uncoated pits
and is considered as the site of important dynamic and regulatory
events at the plasma membrane (72, 73). Caveolins are the prin-
cipal proteins in the caveolae, and caveolin-3 (encoded by gene
CAV3) is specifically found in cardiomyocytes and skeletal muscle
cells. Several cardiac ion channels have been specifically reported
to be localized in the caveolae extracted from cardiac myocytes
that are enriched in caveolin-3 (72, 73). Additionally, components
of the β-adrenergic receptor signaling cascade are also present in
caveolae-enriched membranes (72, 73).
SCN4B encodes for NaVβ4, which is an auxiliary β-subunit of
the cardiac sodium channel. So far only one mutation (L179F)
has been reported in this gene in a Mexican family with multiple
affected family members (74). Mutation in this gene was found to
result in gain of function of the Nav1.5 current (74).
LQTS11
In the heart, sympathetic regulation of cardiac action potential
duration (APD) is mediated by β-adrenergic receptor (β-AR)
activation, which requires assembly of AKAP9 (Yotiao) with the α-
subunit (KvLQT1) of the IKs channel. Mutation in AKAP9 causes
LQTS11 (75). To date only one mutation, S1570L, in AKAP9 has
been reported (75).
LQTS12
Mutation in the α-1-Syntrophin (SNTN1) gene are causal to
LQTS12. Mutation in this gene leads to gain of function of the
cardiac sodium channel (Nav1.5), which is the pathological basis
of LQTS12 (76).
LQTS13
G protein-coupled, inwardly rectifying potassium channel sub-
unit (Kir3.4) is encoded by the KCNJ5 gene. A loss-of-function
mutation in this gene could cause LQTS13 (77). So far, only one
mutation, G387R, has been described in a Chinese family with
nine patients having this mutation. Reduced plasma membrane
expression of Kir3.4 was suggested as the pathology of LQTS in
the patients.
ACQUIRED LQTS
In addition to the congenital LQTS, another variant of LQTS
known as aLQTS also exist, which is caused by factors and sub-
stances that decrease potassium flux and impair the ability of the
myocardium to repolarize. Well-recognized conditions are female
gender, hypokalemia, and drugs that inhibit cardiac potassium
channels (78–80). A number of commonly prescribed drugs could
also preferentially bind and block the HERG channel (Kv11.1,
a protein encoded by KCNH2 gene) and predisposes to aLQTS
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(79, 80). Recently, it was shown that blockade of IKs could also
contribute to drug-induced aLQTS, specially when repolariza-
tion reserve is compromised (81). Fluoxetine and norfluoxetine
were found to suppress the IKs properties, both in vivo and
in vitro and led to marked LQTS (81). Polymorphisms, D85N
in minK (gene KCNE1), T8A, Q9E in MiRP1 (gene KCNE2),
which are putative β-sub-units of the IKs and IKr channels,
were reported to cause aLQTS (82, 83). Autoimmune LQTS has
also been reported in a patient with IgG containing anti-HERG
antibodies (84).
ELECTROCARDIOGRAPHIC FEATURES IN THE THREE
COMMON FORMS OF LONG QT SYNDROME
Typical ST-T-wave patterns are present in the majority of geno-
typed LQTS patients and can be used to identify LQTS1, LQTS2,
and possibly LQTS3 genotypes (85, 86).
The LQTS1 form of the LQTS is associated with a broadT -wave
without shortening of the QT interval at exercise (Figure 2A).
LQTS2 is associated with low-amplitude, often bifid, T waves
(Figure 2B). LQTS3 is associated with a long iso-electric seg-
ment and a narrow-based, tall T wave (Figure 2C). Pause depen-
dence of TdP onset in congenital LQTS is genotype-specific, being
predominant in LQTS2 but almost absent in LQTS1 (87).
Although patterns may suggest a specific genotype of the LQTS,
exceptions have been frequently found.
GENOTYPE-PHENOTYPE
Long QT syndrome is an autosomal dominant disease. Genotype
and phenotype analysis among the heterozygous mutation carri-
ers have been conducted quite extensively in the LQTS1, LQTS2,
and LQTS3 patients. During childhood, the risk of cardiac events
is significantly higher in LQTS1 males than in LQTS1 females,
FIGURE 2 | Electrocardiogram recordings from patients with LQTS1,
LQTS2, and LQTS3. (A) 12-lead ECG of an 18-year-old male with a KCNQ1
mutation. The QT interval is prolonged (QTc=±500 ms). The ST segment has
a broad base and relatively large amplitude. Conduction interval is normal
(standard calibration). (B) 12-lead ECG of a 14-year-old girl with a KCNH2
mutation. The QT interval is prolonged (QTc±520 ms). The ST segment is
notched in lead V3 and has relatively low amplitude in the extremity leads.
Conduction interval is normal (standard calibration). (C) 12-lead ECG of a
12-year-old boy with a SCN5A mutation. The QT interval is prolonged
(QTc±600 ms). The ST segment has a long (almost) iso-electric segment
with a large, sharp, and narrowT wave. Conduction interval is normal
(standard calibration).
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whereas no significant gender-related differences in risk of car-
diac events were observed amongst LQTS2 and LQTS3 patients
(88–91). During adulthood (also after age 40), LQTS1 and LQTS2
females could have significantly higher risk of cardiac events than
respective males (88–91). In general, lethality of cardiac events
seems to be predominant in LQTS3 patients than in LQTS1 and
LQTS2 patients (91). Women with LQTS have a reduced risk for
cardiac events during pregnancy, but the risk quite increases dur-
ing the 9-month postpartum period, specially in the women with
mutation in the KCNH2 gene (92).
Sudden cardiac death in children could also be caused by muta-
tions in the cardiac ion channel genes (93–96). About 28% of the
children with an unexplained SCD (between 1 and 18 years, mean
age: 12.3± 3.8 years) were carriers of mutations in LQTS causal
genes (97). In SIDS, mutations in SCN5A seemed predominant
(98, 99), but, mutations in KCNQ1, KCNH2, KCNE2, and CAV3,
SCN4B, and SCN3B were also found (100, 101). Intrauterine fetal
deaths were also reported due to defects in cardiac ion channel
genes (12, 102).
CLINICAL MANAGEMENT OF LQTS
Cessation of all drugs that are known to prolong the QT interval
and also the correction of electrolyte imbalances and/or precip-
itating metabolic conditions should be the primary focus while
treating (acquired-) LQTS patients. Symptoms in LQTS are often
adrenergically mediated, therefore restriction of patients’ partici-
pation in athletic activities are generally recommended (24, 25).
The mainstay of clinical therapy for the LQTS is β-blockade.
Long-acting preparations of propranolol, nadolol, and metopro-
lol are usually used, and their efficacy in β-blockade is assessed
by blunting of the exercise heart rate (e.g., by >20%) (24, 25).
Amongst all the β-blockers, propranolol and nadolol are con-
sidered superior than metoprolol in symptomatic patients (103).
Furthermore, β-blockade can also be used as a prophylactic treat-
ment in silent mutation carriers to reduce SCD (24). In a study
by Barsheshet et al. (30), patients with c-loop missense mutations
in the KCNQ1 gene exhibited high risk of life-threatening cardiac
events and they had significant benefits from the treatment with
β-blockers. As women with LQTS2 have an increased risk during
the 9-month postpartum period, β-blockers should be prescribed
to reduce any cardiac events during this high-risk period (92). An
implantable cardioverter–defibrillators (ICDs) can be considered
for patients with recurrent syncope despite β-blocker therapy or
in patients with high risk for cardiac arrest (e.g., symptomatic
LQTS2 and LQTS3 with a documented QTc prolongation). Left
cardiac sympathetic denervation (LCSD) is recommended for high
risk LQTS patients in whom an ICD is contraindicated or refused
and β-blockers are either not effective, not tolerated, not accepted
or contraindicated (18, 104). JLNS patients usually have a QTc
>500 ms and are also at high risk, β-blockers have insufficient
FIGURE 3 | Pedigree drawing of the family-1 and 2 with autosomal
recessive LQTS1, probands are shown with an arrow. ECGs from the
probands in two families are shown in the middle, with a QTc of 557 and
529 ms, respectively. Intronic mutation, c.387 −5 T>A in the KCNQ1 gene
was found in the patients (shown in the bottom). Mutation was shown
with an arrow. Non-filled circles and squares are non-carriers for the
mutation. Affected individuals are shown as filled circles (female) and
squares (male). Half filled squares and circles are individuals with
heterozygote mutation. Deceased individuals are indicated by slashes,
probands are indicated by an arrow and consanguineous marriage is
indicated by=Exon− intron boundary is shown by a dotted line with arrow
pointing toward exon.
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efficacy in such patients in whom an early therapy with ICD was
recommended (18, 31).
LQTS: SAUDI PERSPECTIVE
First report on LQTS from Saudi Arabia was published in 1993
from the Riyadh Armed Forces Hospital (105). Four infants and
young children between 6 and 48 months with history of recurrent
seizures, from a single family, were diagnosed as LQTS (105). Fam-
ily history revealed that two-other extended family members had
similar episodes of sudden loss of consciousness and three-family
members died suddenly (105). In all cases, initial diagnosis was
epilepsy (105). Several years later, two sporadic case reports with
comparatively severer variant of neonatal LQTS combined with 2:1
AV block have been reported (106, 107). All these published clin-
ical reports were without any genetic findings that could explain
the pathophysiology of LQTS in them (105–107).
We, for the first time, have reported genetic defects as a patho-
logical basis of LQTS in similar patients from Saudi Arabia. We
have investigated six-Saudi families with history of syncope and
sudden unexplained deaths of fetus, neonates and children (12–
14). Autosomal recessive LQTS1 was diagnosed in children from
two families (Figure 3). Autosomal recessive LQTS2 was diag-
nosed in two families (Figure 4). In one family, a female patient
was diagnosed with autosomal dominant LQTS2 (Figure 5), the
patient had syncopal attacks during postpartum recovery period
at the hospital, which is very common in KCNH2 mutation carrier
women. In all our patients, identification of pathogenic mutations
in the LQTS causal cardiac ion channel genes led to a confirmed
clinical diagnosis, which were misdiagnosed as epileptic convul-
sions before being referred to us (13, 14) Recently, Shinwari et al.
(15) from King Faisal Specialist Hospital and Research Centre
reported a LQTS1 causal KCNQ1 mutation, H258P, in a large
family with 12 affected individuals. Only two carriers were symp-
tomatic, their QTc were >500 ms, and β-blockers suppressed the
clinical symptoms in one patient and the second symptomatic
patient required an ICD.
Genetic and clinical findings in our study (12–14) from Saudi
Arabia are quite intriguing for several reasons: (1) In total, we
have investigated six-families, among them four were homozy-
gous/compound heterozygous for the mutations and the muta-
tions originated from an ancestral source; (2) All the mutations
in LQTS were novel, reported only in these Arab families; (3) Due
to the homozygosity or compound heterozygosity for the muta-
tions, clinical phenotypes were also severe in our studied families
(12–14). We suggested that the genetic and phenotypic observa-
tions stemmed from the extreme high rate of consanguineous
FIGURE 4 | Pedigree drawing of the family-3 and 4 with autosomal
recessive LQTS2. ECG of the proband from family-4 is shown below the
pedigree drawing, which shows sinus tachycardia, almost complete AV block,
wide complex escape rhythm with very long QTc intervals (QT >600 ms).
Mutation, c.3208 C>T (p.Q1070X) in the KCNH2 gene was found in the
patients (shown on the right), marked with an arrow.
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FIGURE 5 |Top left: pedigree of the family-5. Affected individual is shown
by filled circle (female) Proband is indicated by an arrow. 12-lead ECG of the
proband (I:2). ECG shows a high peaked, broad based, large amplitudeT
wave, QTc interval is 580 ms. Screening of the KCNH2 gene shows
substitution of nucleotide “G” for an “A” (c.2362G>A, arrow marked), which
leads to amino acid substitution, p.E788K.
marriages in Saudi Arabia (108, 109). Our study provided the
first scientific evidence about the role of consanguinity in exert-
ing a pivotal role in unexplained cardiac arrhythmias and SCDs
in children and adolescents in Saudi Arabia (12–14). We have also
shown that the KCNQ1 mutation c.387 −5 T>A (NM_000218)
(Figure 3) had spread in the Assir province of Saudi Arabia
from a common ancestor during several generations due to high
incidence of consanguineous marriages [see the map, Figure 6;
(12–14)]. So far, this is the most common LQTS1 causal muta-
tion in Saudi Arabian population, which was also observed at
King Faisal Specialist Hospital and at Khamis Mashayt Military
Hospital (unpublished). A similar result was also obtained for
LQTS2 causal mutation, c.3208 C>T (p.Q1070X) (Figure 4) in
the KCNH2 gene (12, 14), which is also a founder mutation in
Saudi Arabia and segregated during many generations in the Assir
region (see the map, Figure 6). We would predict that there exist
a considerable number of individuals with the mentioned ances-
tral/founder mutations (both in KCNQ1 and KCNH2 and other
genes) in this region and also in the big cities like Riyadh, Jeddah
and Dammam due to urban migration. More founder or ancestral
mutations pathogenic to LQTS are very much envisaged in other
provinces of Saudi Arabia due to high rate of consanguineous
marriages.
As LQTS is an autosomal dominant disease, we expected to
observe predominantly heterozygous mutation carrier patients.
But in our study, we mainly identified patients with recessive
mutations (12–14). Clearly, these patients become first sympto-
matic and, were predominantly referred to Prince Sultan Cardiac
Centre, bringing them under our attention. Nevertheless, findings
from our investigations implies to the fact that recessive LQTS
could have fatal clinical phenotypes in children, and they are not
uncommon in Saudi Arabia (12–14). As the heterozygous muta-
tion carriers are also susceptible to develop arrhythmia and its
complications, concerted initiative should be taken to bring the
local general physicians, cardiologists, and clinical geneticists in a
common platform to identify the individuals at risk. Further, at the
moment, we have also no genetic information for other familial
arrhythmia disorders, e.g., CPVT, SQTS, BrS, AF, etc. Special-
ized cardiogenetic centers should take the initiative to search for
the genetic defects, mutations, and perform genotype-phenotype
studies in all forms of hereditary arrhythmias. It also should be
kept in consideration that not all genetic arrhythmias would have
a family history, as in many cases arrhythmia causal mutation are
de novo in origin, i.e., the proband is the first patient in that family
with the mutation and he/she is the source to transmit the muta-
tion in downstream generations (110, 111). Due to the very high
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FIGURE 6 | Map of Saudi Arabia (courtesy:Wikipedia). Assir region is
marked with thick line, where we have found the founder mutations in
KCNQ1 and KCNH2 genes, described in family 1–4.
rate of consanguineous marriages in Saudi Arabia, we expect a lot
more founder mutations exert a crucial role in congenital arrhyth-
mias in this country. Identifying these founder mutations should
be our first and foremost task, which would facilitate us in devel-
oping an effective premarital and also pre-symptomatic genetic
counseling in this country. Mutations in LQTS causal genes could
confer variability in clinical penetrance, in one extreme, some car-
riers could be presumably completely healthy, but some carriers
could have their first manifestation of the disease as syncope or
sudden death. Sudden death of a young child or adult poses a
great deal of psychological and emotional burden on the family,
screening of the carriers are essential as there exist simple med-
ication, e.g., β-blockers (also behavior modification), which could
very effectively prevent the carriers from the fatal consequences of
arrhythmia and SCDs. Individuals with homozygous mutations in
the LQTS causal genes could have severe morbidity and extreme
high rate of mortality including fetal brady-tachyarrhythmias, and
in many cases miscarriages, spontaneous abortions in the pregnant
mothers (12–14).
Not much research has also been conducted in Saudi Arabia
about the prevalence of various SNPs in the arrhythmia linked
genes and also in the genes that regulate them. Splawski et al. (112)
described a common S1103Y variant in the SCN5A gene associated
with arrhythmia in African-Americans. The variant allele termed
Y1103 is responsible for accelerating channel activation, thereby
enhancing the probability of cardiac arrhythmias in persons of
African descent (52, 112). K393N is a variant in KCNQ1 gene
reported in LQTS1 patients in USA, but, in the Arab population
we have detected this variant in 2% of individuals (unpublished
data). Whether, K393N variant in KCNQ1 gene in Arabs is com-
parable to the S1103Y (SCN5A) variant in African-Americans or
the D85N (KCNE1) variant in the Japanese population could also
merit investigation (59).
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